HOVON 168: Epcoritamab in Addition to R-Mini-CHOP Compared to R-Mini-CHOP in Elderly, Frail or Unfit Patients with Diffuse Large B-cell Lymphoma

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-524230-25-00

Enrollment

Registered

2026-08-31

Start date

Unknown

Completion date

Unknown

Last updated

2026-09-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diffuse large B-cell lymphoma (DLBCL)

Brief summary

The dual primary endpoints are: 1. Complete remission (CR) on or after the End of Treatment (EOT) and 2. • PFS, defined as the duration from the date of randomization to the date of disease progression or death

Detailed description

Overall survical, MRD negativity, Best overall response, Complete Response, Duration of CR and BOR, Changes in PRO, Duration of MRD negativity, Safety data using descriptive statistics

Interventions

DRUGMabThera 100 mg concentrate for solution for infusion

DRUGEpcoritamab (GEN3013)

DRUGMabThera 1400 mg solution for subcutaneous injection

DRUGMabThera 500 mg concentrate for solution for infusion

Eligibility

Sex/Gender

All

Age

65 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The dual primary endpoints are: 1. Complete remission (CR) on or after the End of Treatment (EOT) and 2. • PFS, defined as the duration from the date of randomization to the date of disease progression or death	—

Secondary

Measure	Time frame
Overall survical, MRD negativity, Best overall response, Complete Response, Duration of CR and BOR, Changes in PRO, Duration of MRD negativity, Safety data using descriptive statistics	—

Outcome results

None listed

Source: EU CTIS · Data processed: Sep 2, 2026